December 15, 2025
Report issued: DECEMBER 2025 EXECUTIVE SUMMARY OF 2025 PROJECTS & WORKFLOWS, LISTED ALPHABETICALLY DECOY Therapeutics, Cambridge MA, USA (acting) Chief Medical Officer & Chair, Scientific Advisory Board comprised of Harvard University Medical School Faculty of Experts, Boston MA. GATES Foundation collaboration pursued in...
October 13, 2025
Within the framework of our Consulting services, we have been collaborating since June 2024 with VECTOR BIOSCIENCES, a University of Cambridge, UK, spin-off. Co-founder, Professor David Fairen-Jimenez leading R&D by a talented Team, applying Metal Organic Frameworks, to Drug Delivery. A 15-year track record behind this platform is...
July 11, 2025
JUNE 2025 Shahin Gharakhanian MD Consulting LLC [Est. 2012] @ INTERNATIONAL BIO CONVENTION, BOSTON, 16–19 June, 2025 @ Sponsor, France Pavilion, Exhibit Area, BIO Convention, 16–19 June, 2025 @ Boston Paris Biotechnology Summit™, 15 June 2025. [Co-founder/Program Chair] Reference: www.bostonbiotechnologysummit.com • Dr. Shahin Gharakhanian...
November 7, 2024
Report issued: NOV.2024 ACTIVITIES & PROJECTS’ LISTED ALPHABETICALLY BELOW EXECUTIVE SUMMARY OF 2024 PROJECTS & WORKFLOWS DECOY Therapeutics, Cambridge MA, USA (acting) Chief Medical Officer & Chair, Scientific Advisory Board comprised of Harvard University Medical School Faculty of Experts, Boston MA. GATES Foundation...
May 28, 2024
8th BOSTON BIOTECHNOLOGY SUMMIT™ The Boston Paris Biotechnology Summit™ 2024, a key in-person meeting, also Live Streamed internationally brought Two Hundred (n=200) biopharmaceutical professionals [50% CEO and C-level Executives] to CIC CAMBRIDGE, 02142 Cambridge MA, 15 May 2024 to discuss the Economy & Investment, showcased Award-Winning...
June 8, 2023
Summit Mission An exclusive, Trans-Atlantic bridge designed to foster innovative synergies between biotech and pharma companies, healthcare-focused cities, and regional clusters, institutional, philanthropic and strategic investors. The Summit’s intent is to spark projects, their financings and strategic deals to solve unmet medical needs...
July 20, 2022
Selected Projects listed in alphabetical order: [ACTICOR-BIOTECH, Paris, France] US Medical Executive for Acticor BiotechDeveloping Glenzocimab, a humanized monoclonal antibody fragment directed against platelets glycoprotein VI (GPVI). Primary Indication = Stroke.ACTISAVE phase II/III Study [(NCT05070260] ongoing.Please refer to : www.acticor-biotech.com [DECOY...
January 6, 2022
[ACTICOR-BIOTECH, Paris, France] US Operations’ Collaboration [Press Release] November 4, 2021 at 06:30 pm CET – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, today announces that the U.S Food and Drug Administration (FDA) has provided clearance for...
November 8, 2021
Shahin Gharakhanian had the honor to accept on behalf of ACTICOR-BIOTECH – the PRIX GALIEN MEDSTARTUP 2021 – Award in the «collaboration» category recognizing joint work with the Memorial Hermann Hospital in Houston, Tx. Ceremony held at the Alexandria Life Sciences Center in New York 28 Oct. 2021. We are developing Glenzocimab, a humanized...
October 12, 2021
Prevention of Covid-19 Transmission Beyond the Needle: DCOY101, a novel antiviral fusion peptide-based prophylactic nasal spray. Barbara Hibner*, Peter Marschel*, Frederick E. Pierce II*, Shahin Gharakhanian** *Research & Development Program Team, **Scientific Advisory Board, DECOY Therapeutics, CAMBRIDGE MA, USA. [Contact:...